U.S. Markets closed

Eisai Co., Ltd. (4523.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
Add to watchlist
9,094.00+2.00 (+0.02%)
As of 11:05AM JST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9,092.00
Open9,035.00
Bid9,088.00 x 0
Ask9,095.00 x 0
Day's Range9,005.00 - 9,103.00
52 Week Range6,705.00 - 12,765.00
Volume280,000
Avg. Volume2,866,670
Market Cap2.607T
Beta (5Y Monthly)0.50
PE Ratio (TTM)61.91
EPS (TTM)146.90
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & Yield160.00 (1.33%)
Ex-Dividend DateSep 29, 2021
1y Target Est11,480.00
  • Biogen - Eisai Launch 5-Year Study To See How Well Alzheimer's Drug Aduhelm Works In Real World
    Benzinga

    Biogen - Eisai Launch 5-Year Study To See How Well Alzheimer's Drug Aduhelm Works In Real World

    Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) launched a real-world, Phase 4 study to evaluate the long-term effects of the Aduhelm (aducanumab-avwa) 100 mg/mL solution for injection this time, with a focus on recruiting more patients from minority groups. The companies are looking for 6,000 Alzheimer’s patients with mild cognitive impairment or mild dementia to participate in an observational study dubbed ICARE AD-US. After taking Aduhelm, patients in the study will be monitored rough

  • Reuters

    Biogen, Eisai report design of real-world study of Alzheimer's treatment

    Biogen Inc and partner Eisai Co Ltd on Thursday revealed the design of an upcoming study of their controversial Alzheimer's treatment, Aduhelm. The study, designed to collect real-world, long-term effectiveness and safety data on Aduhelm, will enroll 6,000 patients over fours years in the United States, according to details released during the Alzheimer's Association International Conference. The current study is not the highly anticipated confirmatory trial the U.S. Food & Drug Administration required as part of Aduhelm's accelerated approval, but is one of the three trials Biogen will undertake to generate post-approval data on the drug.

  • Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients
    Benzinga

    Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients

    An analysis of Phase 3 data presented by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) of its Alzheimer's therapy Aduhelm (aducanumab) showed the treatment slowed cognitive, functional, and behavioral decline in the early stages of the disease. Treatment effects were exhibited across all three cognitive and three functional domains measured by Clinical Dementia Rating-Sum of Boxes (CDR-SB), the EMERGE study's primary endpoint. Treatment effects were observed across Alzheimer's Disease